The ability of DR5 to selectively induce apoptosis in numerous cancers in vitro and in vivo ignited a series of enthusiasm to develop its agonists as therapeutics for AML and ALL. This evidence concerns the gene TNFRSF10B and acute lymphoblastic leukemia.